Kevin Shi
Associate
Get their honest, personalized take on your startup.
Sign in to pitch Kevin →At a glance
- Full Name
- Kevin Shi
- Title
- Associate (Investment Team) — during his 2019–2021 tenure at Linden Capital Partners
- Firm
- Linden Capital Partners (Linden, LLC)
- Firm Type
- Private equity — healthcare/life-sciences buyout specialist (NOT an angel/seed investor; the stub's "Angel Investors / Seed Round" labeling does not match the firm behind this email and phone)
- Investment Stage
- Middle-market control buyouts / growth equity (firm-level)
- Check Size
- Firm-level — equity investments in platforms with roughly $50M–$500M+ enterprise value; Linden manages ~$7.9B AUM
- Target Company Profile
- Middle-market healthcare platforms in medical products, specialty distribution, pharmaceutical, and healthcare services
- Sector Focus
- Healthcare and life sciences (exclusive)
- Geographic Focus
- Primarily North America
- Location
- Chicago, IL (110 North Wacker Drive)
Background
Kevin Shi joined Linden Capital Partners as an Associate on the investment team in 2019. Prior to Linden, he was an Investment Banking Analyst at Macquarie Capital, where he focused on M&A advisory and capital-raising transactions. In the private-equity role at Linden he evaluated healthcare and life-sciences buyout opportunities and supported portfolio-company work — the firm's stock-in-trade of medical products, specialty distribution, pharmaceutical, and services platforms.
Shi holds an Honours Business Administration (HBA) degree from the Ivey Business School at Western University (University of Western Ontario), reportedly alongside a Bachelor of Medical Sciences from the same institution — a science-plus-business pairing that fits Linden's healthcare specialization.
Public records indicate Shi's tenure at Linden ran approximately 2019–2021, after which his profile is associated with a research-analyst role at Millennium Management (a multi-strategy hedge fund). The contact stub in this brief ([hidden] / 312-506-5600) points to his former seat at Linden Capital Partners rather than a current angel-investing vehicle.
A note on identity: "Kevin Shi" is a common name and several unrelated professionals share it online. The individual described here is specifically the one with the Ivey Business School / Macquarie Capital background who was an Associate at Linden Capital Partners.
Investment Thesis & Focus
- Linden Capital Partners invests exclusively in healthcare and life sciences — the firm describes itself as "Private equity. Healthcare focus."
- Strategy rests on three pillars: (i) healthcare/life-science industry specialization, (ii) integrated private-equity and operating expertise, and (iii) strategic relationships with large corporations (e.g., carve-outs and partnered acquisitions).
- Targets middle-market platforms across medical products, specialty distribution, pharmaceutical, and healthcare-services segments — control buyouts rather than seed/angel checks.
- As an Associate, Shi's role was deal execution and diligence within this thesis, not independent thesis-setting; there is no public record of a personal angel/seed thesis under his name.
Notable Investments
- LifeStyles Healthcare — sexual-wellness products maker; Linden acquisition announced December 2022.
- Linden's broader portfolio spans medical device, diagnostics, specialty pharma, and healthcare-services companies; the firm reports having invested more than $5 billion in healthcare businesses to date.
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.